Eris Lifesciences Financial Statements
Quarterly
Yearly
| Particulars | Mar '21 | Jun '21 | Sep '21 | Dec '21 | Mar '22 |
|---|---|---|---|---|---|
| Revenue | 278.21 | 349.27 | 359.67 | 332.16 | 305.95 |
| Expenses | 195.15 | 237.26 | 234.81 | 227.32 | 227.41 |
| EBITDA | 83.06 | 112.01 | 124.86 | 104.84 | 78.54 |
| EBIT | 71.60 | 97.50 | 109.90 | 87.96 | 60.18 |
| Profit Before Tax | 84.73 | 117.10 | 130.78 | 108.98 | 85.34 |
| Net Profit | 68.25 | 106.66 | 118.39 | 100.77 | 80.30 |
| Financial Ratios | |||||
| Operating Profit Margin | 29.86% | 32.07% | 34.72% | 31.56% | 25.67% |
| Net Profit Margin | 24.53% | 30.54% | 32.92% | 30.34% | 26.25% |
| Earning Per Share (Diluted) | 5.01 | 7.85 | 8.71 | 7.41 | 5.91 |
| Dividends Per Share | NA | NA | 6.01 | NA | NA |
